- Created on the 1 February, 2017.
Human osteocalcin ELISA kit is a reliable quantitative procedure for measuring osteocalcin (OST) in human serum. This assay has a sensitivity detection limit of 0.8 ng/ml.
Osteocalcin (OST) which is also called bone Gla protein (B.G.P) is a 49 amino-acids peptide which contains three residues of gamma carboxyl glutamic acids and is 5800 Da in molecular weight. It is synthesised in the bone by the osteoblasts where after its production it is partly incorporated in the bone matrix, the rest of it is found to be circulating in blood. There are a large number of publications which show a direct correlation between the rate of bone formation and the levels of circulating osteocalcin but the exact physiological function is yet still unclear.
In clinical application determining the levels of osteocalcin is helpful in many cases for example when:
(a). monitoring bone metabolism during the perimenopause and post-menopause.
(b). monitoring bone metabolism in patients that have growth hormone deficiency, chronic renal failure, hypothyroidism and hyperthyroidism.
(c). identifying women that are at potential risk of developing osteoporosis.
(d). monitoring bone metabolism during treatment of premenopausal women with LH-RH agonists and hormone replacement therapy.
Reagents which are supplied with the following osteocalcin ELISA kit, please following instructions for storage conditions.
1. Microtiter Plate: anti-OST monoclonal antibodies coated.
2. Conjugate: HRP labelled anti-OST (monoclonal antibodies)
3. Calibrator (1-5)
4. Zero Calibrator.
5. Controls 1+2.
6. Washing Solution.
7. Chromogen: TMB.
8. Stop Solution.
The minimum sensitivity detection limit of OST using current human osteocalcin ELISA kit was approximately 0.8 ng/ml. The dynamic range for this assay is 1.9 – 90.0 ng/ml.
- Osteocalcin: a potential marker of metastatic bone disease and response to treatment. Eur. J. Cancer Clin. Oncol.(1988) 24,1211-1217. R.E. Coleman, et al.
- Osteocalcin: Diagnostic Methods and Clinical Applications. Crit. Rev. Clin. Lab. Sci. (1991) 28, 4, 287-335. M.J. Power and P.F. Fottrell.
- An evaluation of serum osteocalcin in Paget’s disease of bone and its response to diphosphonate treatment. Arthritis and Rheumatism (1988) 31, 9, 1142-1147. L.A. Coulton, et al.
- Serum BGP: a specific marker for bone formation in postmenopausal osteoporosis. The Lancet (1984) 1091-1093. J.P. Brown et al.
- Full Name: Osteocalcin (OST) ELISA Kit
- Reactivity: Human
- Sample Type: Serum
- Sensitivity: 0.8 ng/ml
OTHER RELATED ELISA KITS